Flosonics Medical – a leader in wearable medical ultrasound – announced a Series C funding round at $20 million. The funding round was led by New Leaf Venture Partners, with participation from previous investors Arboretum Ventures, Genesys Capital, and iGan Partners.
This new funding round will support Flosonics as the company continues innovating and driving market adoption of FloPatch, a first-in-class wearable Doppler ultrasound for hemodynamic assessments. Vijay Lathi (an experienced MedTech investor focusing on data convergence and guiding growth-stage companies) will join Flosonics Medical’s board of directors.
Flosonics Medical plans to utilize the Series C funding round to accelerate commercial growth, expand indications for use, and continue evidence generation. And the company aims to address the growing demand for wearable AI-assisted sensors to improve patient management inside and outside the hospital.
KEY QUOTES:
“We are thrilled to have New Leaf Venture Partners lead our Series C round and welcome Vijay Lathi to our board. This investment not only validates our past successes but also enables us to accelerate our plans for expansion and innovation. We are committed to leveraging this funding to further enhance the standard of care for critically ill patients with FloPatch and expand our reach into new markets.”
– Joe Eibl, CEO of Flosonics Medical
“Our investment into Flosonics is driven by the clear and significant impact their technology will have on patients in critical situations, and the quality of the team behind it. Flosonics Medical stands at the forefront of wearable ultrasound, and we look forward to contributing to their continued success.”
– Vijay Lathi of New Leaf Venture Partners
